Trial | NCT03938662  Report issue

Title

S-adenosylmethionine Plus Choline in Treatment of Patients With Alcoholic Liver Disease
Randomised Controlled Trial Assessing the Effect of S-adenosylmethionine Plus Choline in Treatment of Patients With Alcoholic Liver Disease

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    44
The study will assess the effect of treatment with formulation containing S-Adenosyl methionine and choline, on patients with alcoholic liver disease.

Half of the patients included will receive named formulation once daily for 24 weeks while other half will receive placebo.
Choline and S-Adenosyl methionine are nutrients both showing hepatoprotective effects.

Choline helps liver metabolise glucose and lipids and repair cell membrane. S-Adenosyl methionine is essential for the synthesis of glutathione, a main cellular antioxidant showing its protective effect against free radicals, among others in liver tissue. Furthermore S-Adenosyl methionine is involved in regulation of hepatocyte growth, differentiation, and death. It also enables endogenous production of small amount of choline. Although human organism has capacity for production of small amount of S-Adenosyl methionine, damaged liver can not produce it or produce it insufficient amounts.

Having this in mind it can be hypothesised that administration of choline and S-Adenosyl methionine can be beneficial in patients with alcoholic liver disease.
Study Started
May 09
2019
Primary Completion
Apr 01
2020
Anticipated
Study Completion
Apr 01
2020
Anticipated
Last Update
May 29
2019

Dietary Supplement formulation containing S-Adenosyl methionine and choline [choline, s-adenosyl methionine]

Patients will be administered with formulation containing S-Adenosyl methionine and choline once daily for the period of 24 weeks.

Dietary Supplement Placebo

Placebo of same appearance, colour and taste,

S-Adenosyl methionine and choline Experimental

Patients in will be administered with formulation of 100 mg of S-Adenosyl methionine and 82.5 mg of choline, once daily for 24 weeks.

Placebo Placebo Comparator

Patients in will be administered with placebo once daily for 24 weeks.

Criteria 

Inclusion Criteria:

alcoholic liver disease

Exclusion Criteria:

hepatitis B
hepatitis C
autoimmune hepatitis
hemochromatosis
Wilson's disease
hepatocellular carcinoma
No Results Posted